|March 3, 2014|
|06:16 EDT||RHHBY||Genentech says IDMC recommends Phase III METLung study be stopped|
Genentech, a member of the Roche Group, announced that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy. The study evaluated if onartuzumab in combination with Tarceva helped people with previously treated, advanced non-small cell lung cancer whose tumors were identified as MET-positive live longer compared to Tarceva alone. Overall adverse event rates were generally similar between the two groups. Data will be submitted for presentation at an upcoming medical meeting. "These results are disappointing because new options are needed for people with lung cancer, the most common and deadly cancer worldwide,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "We remain committed to helping people with lung cancer and are studying several investigational medicines in this disease.” Genentech is evaluating the implications of the METLung study results across the ongoing onartuzumab clinical program.
News For RHHBY From The Last 14 Days
|April 22, 2015|
|05:27 EDT||RHHBY||Roche sees FY15 core EPS to grow ahead of sales at constant exchange rates|
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
|05:27 EDT||RHHBY||Roche reports Q1 group sales CHF 11.83B vs. CHF 11.50B|
Subscribe for More Information
|April 21, 2015|
|07:06 EDT||RHHBY||Bina Tech, AstraZeneca announce collaborative agreement for GMS|
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
|05:33 EDT||RHHBY||Inovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB|
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
|April 17, 2015|
|05:32 EDT||RHHBY||Accelerate Diagnostics appoints Pete Bantock to Chief Culture Officer|
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
|April 16, 2015|
|08:04 EDT||RHHBY||Roche granted orphan status for lymphoma treatment|
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
|April 14, 2015|
|06:30 EDT||RHHBY||Roche to seek to have cancer drug tested in 11 trials in 2015, Reuters says|
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
|April 13, 2015|
|10:01 EDT||RHHBY||Roche acquires CAPP Medical|
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.